Migraine Treatment Optimization Questionnaire-4 (mTOQ-4)

ورودی‌های بالینی بیمار

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
mtoq 4 score
—points
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Very Poor0–0
  • Poor1–5
  • Moderate6–7
  • Maximum8–8
Direct Clinical Answer

The Migraine Treatment Optimization Questionnaire-4 (mTOQ-4) calculates quantifying neurological deficit severity, stroke volume, and reperfusion therapy eligibility. Key inputs include pain free 2 hours. Scores guide initiating intravenous thrombolysis, activating endovascular thrombectomy pathways, or secondary prevention protocols. This standardized assessment improves clinical decision safety and bedside patient management.

Clinical Guidelines & Evidence

Determines effectiveness of current migraine treatment plan to guide treatment optimization decisions

Clinical Indication

The Migraine Treatment Optimization Questionnaire-4 (mTOQ-4) is indicated for bedside clinical practice to support Determines effectiveness of current migraine treatment plan to guide treatment optimization decisions. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients presenting with acute neurological deficits, acute ischemic stroke, intracranial hemorrhage, seizures, or altered mental status. Clinical application is indicated across Comprehensive stroke centers, acute neurovascular units, neuro-ICU, and emergency neurology services.

Limitations & Contraindications

Stroke mimics including severe hypoglycemia, Todd postictal paresis, and hemiplegic migraine must be ruled out prior to intravenous thrombolysis.

Clinical Pearls & Action Plan

Time is brain; rapid determination of Last Known Well time and baseline functional status dictates reperfusion eligibility. Guideline pearl: Higher scores indicate better treatment optimization and lower risk of chronic migraine.

Formula & Variables:

mTOQ-4 Score = Q1 + Q2 + Q3 + Q4 (where 0=never/rarely, 1=less than half the time, 2=half the time or more)

Input Parameters

NameTypeRequiredDescription
pain_free_2_hoursstringYesAfter taking your migraine medication, are you pain-free within 2 hours for most attacks?
relief_24_hoursstringYesDoes 1 dose of your migraine medication usually relieve your headache and keep it away for at least 24 hours?
able_to_planstringYesAre you comfortable enough with your migraine medication to be able to plan your daily activities?
feel_in_controlstringYesAfter taking your migraine medication, do you feel in control of your migraines enough so that you feel you can return to normal function?

Score Interpretation & Guidance

RangeStageDescription
0–0Very PoorVery poor treatment efficacy
1–5PoorPoor treatment efficacy
6–7ModerateModerate treatment efficacy
8–8MaximumMaximum treatment efficacy

Evidence-Based References (EBM)

  • Lipton RB, Kolodner K, Bigal ME, Valade D, Láinez MJ, Pascual J, et al. Validity and reliability of the migraine-treatment optimization questionnaire. Cephalalgia. 2009 Jul;29(7):751-9. doi: 10.1111/j.1468-2982.2008.01786.x.DOI: 10.1111/j.1468-2982.2008.01786.x
  • Lipton RB, Fanning KM, Serrano D, Reed ML, Cady R, Buse DC. Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. Neurology. 2015 Feb 17;84(7):688-95. doi: 10.1212/WNL.0000000000001256.DOI: 10.1212/WNL.0000000000001256
  • Silberstein SD, Lipton RB, Dodick DW, Goadsby PJ, Freitag F, Mathew N, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache. 2007 Feb;47(2):170-80.

Related calculators